Here are the 10 biggest Houston health tech stories of the year. Photo courtesy JLABS.

Editor's note: As 2025 comes to a close, we're looking back at the stories that defined Houston innovation this year. The Bayou City continued to grow as a health tech hub, bringing in a multibillion-dollar pharmaceutical development, playing home based to startups developing innovative treatment options and attracting leading researchers and professionals to the city. Here are the 10 most-read Houston health tech stories of the year:

Houston Nobel Prize nominee earns latest award for public health research

Dr. Peter Hotez with Dr. Maria Elena Bottazzi. Photo courtesy of TMC

Houston vaccine scientist Dr. Peter Hotez is no stranger to impressive laurels. In 2022, he was nominated for a Nobel Peace Prize for his low-cost COVID vaccine.

His first big win of 2025 was this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project, which aims to create a predictive disease atlas relating to climate disasters. Rice University researchers are collaborating with Hotez and his team on a project that combines climate science and metagenomics to access 3,000 insect genomes. The goal is to aid health departments in controlling disease and informing policy. Continue reading.

U.S. News ranks Houston hospital No. 1 in Texas for 14th year in a row

Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report's 2025 rankings of the best hospitals in Texas prove that Houston is in good hands.

The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35. Continue reading.

Eli Lilly to build $6.5B pharmaceutical factory at Generation Park

Eli Lilly is expected to bring a $6.5 billion manufacturing facility to Houston by 2030. Rendering courtesy Greater Houston Partnership.

Pharmaceutical giant Eli Lilly and Co. plans to build a $6.5 billion manufacturing plant at Houston’s Generation Park. More than 300 locations in the U.S. competed for the factory.

The Houston site will be the first major pharmaceutical manufacturing plant in Texas, according to the Greater Houston Partnership. Lilly said it plans to hire 615 full-time workers for the 236-acre plant, including engineers, scientists and lab technicians. The company will collaborate with local colleges and universities to help build its talent pipeline. Continue reading.

How a Houston company is fighting anxiety, insomnia & Alzheimer’s through waveforms

Nexalin develops non-invasive devices that help reset networks in the brain associated with symptoms of anxiety and insomnia. Photo via Getty Images.

Houston-based Nexalin Technology is taking a medicine-free approach to target brain neurologically associated with mental illness. The company's patented, FDA-cleared frequency-based waveform targets key centers of the midbrain. Delivered via a non-invasive device, the treatment gently stimulates the hypothalamus and midbrain, helping to “reset networks associated with symptoms” of anxiety and insomnia.

Nexalin’s proprietary neurostimulation device moved forward with a clinical trial that evaluated its treatment of anxiety disorders and chronic insomnia in Brazil this year and enrolled the first patients in its clinical trial at the University of California, San Diego. Continue reading.

Houston doctor aims to revolutionize hearing aid industry with tiny implant

Houston Methodist's Dr. Ron Moses has created NanoEar, which he calls “the world’s smallest hearing aid.” Photo via Getty Images.

“What is the future of hearing aids?” That’s the question that led to a potential revolution.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, is the creator of NanoEar, which he calls “the world’s smallest hearing aid.” NanoEar is an implantable device that combines the invisibility of a micro-sized tympanostomy tube with more power—and a superior hearing experience—than the best behind-the-ear hearing aid. Continue reading.

Houston scores $120M in new cancer research and prevention grants

The Cancer Prevention and Research Institute of Texas doled out 73 more grants to health care systems and companies in the state in November. Carter Smith/Courtesy of MD Anderson

The Cancer Prevention and Research Institute of Texas granted more than $120 million to Houston organizations and companies as part of 73 new awards issued statewide this fall. The funds are part of nearly $154 million approved by the CPRIT's governing board, bringing the organization's total investment in cancer prevention and research to more than $4 billion since its inception. A portion of the funding will go toward recruiting leading cancer researchers to Houston. Continue reading.

Digital Health Institute's new exec director aims to lead innovation and commercialization efforts

Pothik Chatterjee was named executive director of Rice University's and Houston Methodist's Digital Health Institute, effective May 1. Photo courtesy Rice University.

The Digital Health Institute, a joint venture between Rice University and Houston Methodist, appointed Pothik Chatterjee to the role of executive director this summer. Chatterjee’s role is to help grow the collaboration between the institutions, but the Digital Health Institute already boasts more than 20 active projects, each of which pairs Rice faculty and Houston Methodist clinicians. Once the research is in place, it’s up to Chatterjee to find commercial opportunities within the research portfolio. Those include everything from hospital-grade medical imaging wearables to the creation of digital twins for patients to help better treat them. Continue reading.

Innovation Labs @ TMC set to launch for early-stage life science startups

Innovation Labs @ TMC will open next year at the TMC Innovation Factory. Photo courtesy JLABS.

The Texas Medical Center announced its plans to launch its new Innovation Labs @ TMC in January 2026 to better support life science startups working within the innovation hub. The 34,000-square-foot space, located in the TMC Innovation Factory at 2450 Holcombe Blvd., will feature labs and life science offices and will be managed by TMC. The expansion will allow TMC to "open its doors to a wider range of life science visionaries." Continue reading.

6 Houston health tech startups making major advancements right now

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health. Photo courtesy Koda Health.

The Health Tech Business category in our 2025 Houston Innovation Awards honored innovative startups within the health and medical technology sectors. Six forward-thinking businesses were named finalists for the 2025 award, ranging from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more. Continue reading or see who won here.

Houston students develop cost-effective glove to treat Parkinson's symptoms

Rice University students Emmie Casey and Tomi Kuye used smartphone motors to develop a vibrotactile glove. Photo by Gustavo Raskosky/ Courtesy Rice University.

Two Rice undergraduate engineering students have developed a non-invasive vibrotactile glove that aims to alleviate the symptoms of Parkinson’s disease through therapeutic vibrations. Emmie Casey and Tomi Kuye developed the project with support from the Oshman Engineering Design Kitchen (OEDK). The team based the design on research from the Peter Tass Lab at Stanford University, which explored how randomized vibratory stimuli delivered to the fingertips could help rewire misfiring neurons in the brain—a key component of Parkinson’s disease. Continue reading.

Pothik Chatterjee was named executive director of Rice University's and Houston Methodist's Digital Health Institute, effective May 1. Photo courtesy Rice University.

Digital Health Institute's new exec director aims to lead innovation and commercialization efforts

new hire

Though our existences have become deeply entangled with technology, our health has been slower to catch up. The creation late last year of the Digital Health Institute was a major step into the future for both Rice University and Houston Methodist, for whom the institute is a joint venture.

The latest news for the Digital Health Institute is the appointment of Pothik Chatterjee to the role of executive director.

“The Digital Health Institute’s collaborative model is uniquely powerful,” Chatterjee told Rice University’s office of media relations. “By bringing together clinicians, engineers and entrepreneurs, we’re building an ecosystem designed to transform how care is delivered and experienced.”

Chatterjee’s role is to help grow the collaboration between the institutions, but the Digital Health Institute already boasts more than 20 active projects, each of which pairs Rice faculty and Houston Methodist clinicians.

“Research is great, but what we really want at the Digital Health Institute is to translate those research findings into products and services that can be used at the patient's bedside,” Chatterjee explained to InnovationMap.

Once the research is in place, it’s up to Chatterjee to find commercial opportunities within the research portfolio. Those include everything from hospital-grade medical imaging wearables to the creation of digital twins for patients to help better treat them.

“As we move from vision to execution, Pothik’s expertise will be essential in helping us strengthen the institutional alignment needed to deliver at scale,” Dr. Khurram Nasir, Houston Methodist’s William A. Zoghbi Centennial Chair in Cardiovascular Medicine and division chief of cardiovascular prevention and wellness, told Rice. “From my vantage point of a health system, the real value lies not just in innovation, but in implementation.”

Nasir’s co-founder is Ashutosh Sabharwal, Rice’s Ernest Dell Butcher Professor of Engineering and professor of electrical and computer engineering.

“The Digital Health Institute is a key step toward advancing health and health care for the benefit of humanity,” Sabharwal said. “We’re thrilled to welcome Pothik to our growing team. His background in health care innovation, research administration and venture investing will be instrumental in translating cutting-edge research into impactful digital health solutions. From leading innovation strategy and forging strong partnerships to driving fundraising and grant development, his leadership will help shape the institute’s long-term success.”

Though Chatterjee has previously worked around the country, including in Boston and Baltimore, he says he believes Houston is uniquely positioned to thrive in the digital health space.

“Houston is the best place to do it, because we have Rice and Houston Methodist,” he told InnovationMap. “[People] want to help keep that innovation in Houston, not just send it off to Silicon Valley or New York or Boston. There seems to be a lot of appetite from the philanthropic community to have homegrown Houston digital health innovation.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”